Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Leukemia, Myeloid, Acute 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Graft vs Host Disease 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 162fludarabine phosphate 127Mycophenolic Acid 96Tacrolimus 92Whole-Body Irradiation 85Busulfan 85Peripheral Blood Stem Cell Transplantation 82fludarabine 79Cyclosporine 68Melphalan 63Antilymphocyte Serum 58Filgrastim 56Methotrexate 55Thiotepa 39Radiotherapy 39Cord Blood Stem Cell Transplantation 34Granulocyte Colony-Stimulating Factor 29Cytarabine 28Methylprednisolone 27Stem Cell Transplantation 26Sirolimus 24thymoglobulin 23Etoposide 23Clofarabine 22Rituximab 19Flow Cytometry 15Cyclosporins 15sargramostim 13Specimen Handling 13Alemtuzumab 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Precursor Cell Lymphoblastic Leukemia-Lymphoma × Maraviroc × Myeloid × Clear all
NCT02208037 2019-01-23

Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

National Heart, Lung, and Blood Institute (NHLBI)

Phase 2 Completed
279 enrolled 28 charts
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Hodgkin Disease, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Leukemia, Myeloid, Acute, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡